Notícia em acompanhamento · 1 reportagem
Trump administration's ibogaine fast-track effort
Em desenvolvimentoPróxima verificação a : Whether the administration or FDA abandons the effort, or the FDA completes a decision on ibogaine’s development or approval pathway.
Ponto da situação
As of July 23, 2026, the Trump administration was pushing to fast-track ibogaine for addiction treatment, while experts cited cardiac risks linked to potentially fatal arrhythmias. The report identifies Trump and the FDA as decision-makers but gives no decision, next step or indication that the effort has been abandoned.
Evolução do temaDia 1
1 reportagem11 órgãos11 fontes1 vídeo
O tema até agora
Twenty-Seven Dead, No FDA Approval, and a Presidential Pen
Trump's April executive order fast-tracks ibogaine, a Schedule I psychedelic with documented cardiac risk, while Americans keep dying at unregulated clinics abroad.
Ainda em aberto após esta reportagem
- The full death toll at foreign clinics, including non-American patients, is not publicly tracked.
- How the FDA will interpret "expedite" — whether it fast-tracks a specific application or reopens the research pathway — has not been disclosed.
- Whether Texas's state-funded trials will produce randomized data sufficient for an FDA submission.
Histórico
Aberta1 reportagem
Quem está envolvido
Pessoas
Céline GounderAmerican infectious disease physician, internist, epidemiologist, filmmaker, and medical journalist1 reportagem
Donald TrumpPresident of the United States (2017–2021; since 2025)1 reportagem
Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 reportagem
Locais
- MexicoMexico1 reportagem
- Stanford University450 Jane Stanford Way, Stanford, CA 94305, USA1 reportagem
- TexasTexas, USA1 reportagem
- The Oval Office1600 Pennsylvania Ave NW, Washington, DC 20500, USA1 reportagem
Todos os órgãos de comunicação que lemos sobre este tema
11 fontes11 órgãos1 vídeo
CBS Newscbsnews.com1
celinegounder.com1
HeyDay News11 vídeo
modeldiplomat.com1
Newsweeknewsweek.com1
